RELENZA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Relenza, and when can generic versions of Relenza launch?
Relenza is a drug marketed by Glaxosmithkline and is included in one NDA.
The generic ingredient in RELENZA is zanamivir. One supplier is listed for this compound. Additional details are available on the zanamivir profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for RELENZA?
- What are the global sales for RELENZA?
- What is Average Wholesale Price for RELENZA?
Summary for RELENZA
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 84 |
| Clinical Trials: | 9 |
| Patent Applications: | 5,019 |
| Drug Prices: | Drug price information for RELENZA |
| What excipients (inactive ingredients) are in RELENZA? | RELENZA excipients list |
| DailyMed Link: | RELENZA at DailyMed |
Recent Clinical Trials for RELENZA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Oxford | Phase 2 |
| Hospital Authority | Phase 3 |
| Food and Health Bureau, Hong Kong | Phase 3 |
Pharmacology for RELENZA
| Drug Class | Neuraminidase Inhibitor |
| Mechanism of Action | Neuraminidase Inhibitors |
US Patents and Regulatory Information for RELENZA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxosmithkline | RELENZA | zanamivir | POWDER;INHALATION | 021036-001 | Jul 26, 1999 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for RELENZA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Glaxosmithkline | RELENZA | zanamivir | POWDER;INHALATION | 021036-001 | Jul 26, 1999 | ⤷ Sign Up | ⤷ Sign Up |
| Glaxosmithkline | RELENZA | zanamivir | POWDER;INHALATION | 021036-001 | Jul 26, 1999 | ⤷ Sign Up | ⤷ Sign Up |
| Glaxosmithkline | RELENZA | zanamivir | POWDER;INHALATION | 021036-001 | Jul 26, 1999 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for RELENZA
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| GlaxoSmithKline Trading Services Limited | Dectova | Zanamivir | EMEA/H/C/004102 Dectova is indicated for the treatment of complicated and potentially life-threatening influenza A or B virus infection in adult and paediatric patients (aged ≥6 months) when:The patient’s influenza virus is known or suspected to be resistant to anti-influenza medicinal products other than zanamivir, and/orOther anti-viral medicinal products for treatment of influenza, including inhaled zanamivir, are not suitable for the individual patient.Dectova should be used in accordance with official guidance. |
Authorised | no | no | no | 2019-04-26 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for RELENZA
See the table below for patents covering RELENZA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| New Zealand | 277789 | CRYSTALLINE N-ACETYL NEUROMINIC ACID DERIVATIVES AND PHARMACEUTICAL USES | ⤷ Sign Up |
| China | 1057260 | ⤷ Sign Up | |
| Hungary | T74938 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for RELENZA
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0526543 | 990030 | Netherlands | ⤷ Sign Up | PRODUCT NAME: ZANAMIVIRUM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT EN/OF VAN EEN FARMACEUTISCH AANVAARDBARE ESTER; NATL. REGISTRATION NO/DATE: RVG 24094 19990707; FIRST REGISTRATION: SE 14997 19990209 |
| 0526543 | SPC/GB99/030 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: ZANAMIVIR, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR DERIVATIVE; REGISTERED: SE 14997 19990209; UK PL10949/0327 19990625 |
| 0208846 | 99C0032 | Belgium | ⤷ Sign Up | PRODUCT NAME: ZANAMIVIR; NAT. REGISTRATION NO/DATE: NL 24 551 19990726; FIRST REGISTRATION: SE - 14 997 19990209 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
